Immunitor Announces Federal Government Research Collaboration

Share Article

Immune Network Ltd., (IMMFF:PK), reports that Immunitor Inc. and the National Research Council of Canada (NRC) have signed a Collaborative Research Agreement (CRA) to support further laboratory analysis of the immune mechanisms underlying the clinical efficacy of Immunitor products.

Immune Network Ltd., (IMMFF:PK), reports that Immunitor Inc. and the National Research Council of Canada (NRC) have signed a Collaborative Research Agreement (CRA) to support further laboratory analysis of the immune mechanisms underlying the clinical efficacy of Immunitor products. A primary purpose of the collaboration with the NRC is to access research support for Immunitor’s candidate vaccines. Immunitor expects the collaboration may lead to further investigation of immune mechanisms of action of Immunitor’s lead products.

The formation of this collaboration with the NRC is part of the initial activities in Immunitor’s plan to relocate to Charlottetown, Canada. Immunitor has already established interactions with several other private and public entities in the vibrant biotech community of Charlottetown, towards additional commercial development of its products, and potential raw material and finished goods GMP manufacturing arrangements. Immunitor plans to expand its laboratory research capacity by growing its collaborative work with the National Research Council of Canada’s Institute for Nutrisciences and Health and other research entities in Charlottetown.

Immunitor’s clinical trials in tuberculosis are meanwhile continuing globally. Encouraging clinical trial results have been published which concern newly-developed buccal formulations of Immunoxel/Dzherelo (botanical extracts), Immunitor V5 (therapeutic vaccine), and Immunitor V7 (Mycobacterium vaccae-based therapeutic vaccine). All products derive from Immunitor’s oral formulation platform technology.

About Immunitor:
Immunitor is dedicated to treatment of immunity-dependent diseases based on its clinically-validated proprietary oral delivery technology to employ the patient's own mucosal immune system. The patented technology platform of Immunitor is applied to vaccines and immunotherapies. Prior issued and pending Immunitor patents cover vaccines against microbial and fungal infections, HIV, hepatitis B, hepatitis C, influenza, tuberculosis, cancer and atherosclerosis. For more information about Immunitor, please visit http://www.immunitor.com.

Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

aldar bourinbayar

13014760930
Email >